

DNA repair pathways as targets for cancer therapy

Helleday, T; Petermann, Eva; Lundin, C; Hodgson, B; Sharma, RA

DOI:

[10.1038/nrc2342](https://doi.org/10.1038/nrc2342)

License:

None: All rights reserved

Document Version

Early version, also known as pre-print

Citation for published version (Harvard):

Helleday, T, Petermann, E, Lundin, C, Hodgson, B & Sharma, RA 2008, 'DNA repair pathways as targets for cancer therapy', *Nature Reviews Cancer*, vol. 8, no. 3, pp. 193-204. <https://doi.org/10.1038/nrc2342>

[Link to publication on Research at Birmingham portal](#)

Publisher Rights Statement:

The definitive, peer-reviewed and edited version of this article is published in Nature Reviews Science, volume 8, issue 3, 2008 [<http://dx.doi.org/10.1038/nrc2342>]"

General rights

Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes permitted by law.

- Users may freely distribute the URL that is used to identify this publication.
- Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private study or non-commercial research.
- User may use extracts from the document in line with the concept of 'fair dealing' under the Copyright, Designs and Patents Act 1988 (?)
- Users may not further distribute the material nor use it for the purposes of commercial gain.

Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.

When citing, please reference the published version.

Take down policy

While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been uploaded in error or has been deemed to be commercially or otherwise sensitive.

If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to the work immediately and investigate.

Targeting DNA repair for anti-cancer therapy

Thomas Helleday^{1,2,*}, Cecilia Lundin¹, Ben Hodgson¹, Eva Petermann¹, Ricky A. Sharma¹

¹Radiation Oncology & Biology, University of Oxford, Oxford OX3 7LJ, UK.

²Department of Genetics Microbiology and Toxicology, Stockholm University, S-106 91 Stockholm, Sweden.

Word count (abstract+glance+text+boxes+legends): 5,258

Abbreviations:

ATM: Ataxia telangiectasia mutated

ATR: Ataxia telangiectasia mutated- and Rad3-related

BER: base excision repair

DSB: double strand break

HR: homologous recombination

NER: nucleotide excision repair

NHEJ: non-homologous end joining

MGMT: O6-methylguanine methyl transferase

MMR: mismatch repair

PARP: poly(ADP-ribose) polymerase

SSBR: DNA single strand break repair

Key words:

DNA replication, repair, cancer, therapy, homologous recombination, PARP

Footnote: *Corresponding author. E-mail: thomas.helleday@rob.ox.ac.uk

ABSTRACT | Chemotherapy often targets dividing cells by causing DNA damage that leads to replication-dependent toxic lesions. Cells possess several overlapping DNA damage repair pathways that allow them to survive these treatments. Inhibitors of DNA repair are therefore used in combination therapy to modulate the efficacy of DNA damaging drugs. Since DNA repair pathways are commonly altered during tumour development, cancer cells will depend on a remaining subset of DNA repair pathways for survival. These remaining pathways can be targeted by DNA repair inhibitors as monotherapy to selectively kill cancer cells. The advantage of DNA repair inhibition as a single agent therapy is that it selectively increases unrepaired endogenous DNA damage in tumour cells and therefore appears to have fewer side effects in non-cancerous cells. DNA damage response and repair inhibitors may also be used to amplify oncogene- or hypoxia-induced replication stress and convert these lesions into fatal replication lesions.

At a glance

- Several anti-cancer chemotherapy drugs work by causing excessive DNA damage that is converted into toxic lesions during DNA replication. Survival is promoted through repair of these lesions by a number of DNA repair pathways that have overlapping substrate specificities. The efficacy of anti-cancer drugs is therefore highly influenced by cellular DNA repair capacity. Inhibitors of DNA repair increase the efficacy of DNA damaging anti-cancer drugs in preclinical models. Small molecule inhibitors of DNA repair have been combined with conventional chemotherapy drugs in several phase I-II clinical trials.
- Tumour development is commonly associated with perturbed DNA damage response and repair pathways. This results in reduced DNA repair capacity and increased genetic instability of tumour cells. DNA repair pathways have overlapping specificities and defects in one pathway can be compensated for by other pathways. These compensating pathways can be identified in synthetic lethal screens and then specifically targeted for treatment of DNA repair-defective tumours.

- Inhibitors of DNA repair can work as single agents for targeted treatment of DNA repair-defective cancers. This hypothesis is currently being tested in phase II trials where patients with breast or ovarian cancers defective in homologous recombination are treated with a PARP inhibitor to target an overlapping pathway, DNA single-strand break repair (SSBR).
 - Tumours often exhibit replication stress as a consequence of oncogene-induced growth signals or hypoxia-induced replication arrest. DNA repair inhibitors could be used to prevent the repair of replication lesions present in tumour cells and convert them into fatal replication lesions that specifically kill cancer cells.
-

Cancer therapy usually involves exposing the body to cytotoxic agents, administered with the aim of killing malignant cells more efficiently than normal tissue. The therapy must therefore exploit specific molecular and cellular features of the cancer it is aiming to eliminate. One fundamental characteristic of cancer cells is that they are rapidly proliferating and therefore most anti-cancer drugs target the cell cycle in various ways. Cell division can be targeted directly by inhibitors of the mitotic spindle, thus preventing equal division of DNA to the two daughter cells. The growth signals that result in entry into the cell cycle can be targeted by hormonal manipulation, therapeutic antibodies and drugs that inhibit growth signalling pathways. However, the most common means of targeting the cell cycle is to exploit the impact of DNA damaging drugs on DNA replication during S phase. When cells attempt to replicate the damaged DNA more severe lesions are generated, thus making DNA damaging treatments more toxic to replicating cells than non-replicating cells. The toxicity of DNA damaging drugs can however be reduced by the activities of several overlapping DNA repair pathways which remove lesions before the onset of DNA replication. DNA repair pathways thus modulate the efficacy of cancer therapy. In addition, they are frequently mutated in cancers. These two features make DNA repair a promising target for novel cancer treatments.

DNA damaging agents in cancer treatment

Many anti-cancer drugs employed in the clinic have been used for several decades and are highly efficient in killing proliferating cells by interfering with DNA replication through a range of different mechanisms (Figure 1). The principal mechanism by which toxicity is achieved is by obstruction of replication fork progression, which can lead to replication fork collapse, resulting in the formation of replication-associated DNA double-strand breaks (DSBs). DSBs are generally considered to be the main toxic DNA lesions that kill cells by induction of apoptosis ^{1,2}.

Common types of DNA damage that interfere with replication fork progression are chemical modifications (adducts) of DNA bases, caused by reactive drugs that covalently bind DNA, either directly or after being metabolised in the body. These *alkylating agents* are grouped in two categories; mono-functional alkylating agents with one active moiety that modifies single bases, while bi-functional alkylating agents have two reactive sites and crosslink two bases within the same DNA strand (intra-strand crosslinks) or between opposite DNA strands (inter-strand crosslinks). Such inter-strand crosslinks pose a complete block to replication forks.

The DNA synthesis process itself is often targeted by chemotherapy, either through the use of replication inhibitors or by *anti-metabolites*. DNA replication inhibitors such as aphidicolin directly inhibit DNA polymerases ³, whereas the radical scavenger hydroxyurea inhibits ribonucleotide reductase, required for production of deoxyribonucleotides (dNTPs) that are used for DNA synthesis ⁴. Replication inhibitors can be regarded as DNA damaging agents because, as explained above, impaired replication fork progression causes DNA lesions including DSBs ^{5,6}. Anti-metabolites resemble nucleotides or nucleotide precursors and act by inhibiting nucleotide metabolism pathways, thus depleting cells of dNTPs. They can also impair replication fork progression by becoming incorporated into the DNA ⁷. In general, the biochemical mechanisms of cell death induced by anti-metabolites are poorly understood.

Another means of interfering with replication is to exploit DNA strand breaks that arise naturally during the process of DNA synthesis. Topoisomerases are a group of enzymes which resolve torsional strains imposed on the double helix during DNA replication. They induce transient DNA breaks to relax supercoiled DNA or allow DNA strands to pass through each other ⁸. Topoisomerase inhibition, a common strategy for

anticancer treatment, prevents re-sealing of these breaks causing replication-associated DSBs^{1,2}.

Ionizing radiation and “radiomimetic” agents such as bleomycin cause replication-independent DSBs that efficiently kill non-replicating cells. However, radiation rapidly prevents replication by activation of cell cycle checkpoints to avoid formation of toxic DNA replication lesions⁹. These cell cycle checkpoints are regulated by effector kinases, such as ATM and ATR¹⁰⁻¹² which regulate the activities of downstream checkpoint proteins such as Chk1 and Chk2. . Defects in DNA damage checkpoint pathways result in sensitivity to a range of anti-cancer treatments, (e.g. loss of ATM results in sensitivity to ionizing radiation¹³) and inhibitors of these checkpoint pathways are being explored in the treatment of cancer, as discussed below.

Chemotherapy-induced DNA lesions are efficiently repaired

DNA repair activity largely determines the efficacy of anti-cancer drugs in causing tumour regression. Direct DSBs are mainly repaired by *non-homologous end joining* (NHEJ)¹⁴, whereas replication-associated DSBs are repaired by *homologous recombination* (HR)¹⁵ and related replication repair pathways, as discussed below. DNA adducts, such as those created by alkylating agents, may be excised and repaired before they are confronted by the replication machinery. This is achieved by *base excision repair* (BER), excising a single damaged DNA base or a short strand containing the damaged base¹⁶ or *nucleotide excision repair* (NER), which excises a single-stranded DNA molecule of approximately 24 to 30 base pairs containing the DNA lesion^{17,18}. Damaged DNA can also be repaired without removal of the damaged base, in a process that directly reverses the DNA alkylation¹⁹. The O6-methylguanine methyl transferase (MGMT) is an *alkyltransferase* and removes alkylations on the O6 position of guanine produced from the anti-cancer drugs such as temozolomide²⁰, and the *DNA-dioxygenases* ABH2 and ABH3 revert 1-methyladenine and 3-methylcytosine back to adenine or cytosine respectively²¹. The repair of alkylated lesions is thought to be quick, with the majority of lesions appearing to be repaired within one hour²². If the lesions are removed before initiation of replication, the efficiency of alkylating agents in killing the tumour is significantly reduced. Thus, modulation of DNA repair clearly influences the efficacy of

alkylating agents, and resistance to alkylating agents is often explained by upregulation of DNA repair proteins.

Whereas most DNA repair pathways mediate resistance to DNA damage, *mismatch repair* (MMR) is actually required for the toxicity of several anti-cancer drugs (Figure 1). This has been explained by the “futile repair cycle” model in which mismatch repair removes the newly inserted intact base instead of the damaged base, triggering subsequent rounds of futile repair which might be deleterious²³. It is also possible that mismatch repair might have an important role in triggering checkpoint signalling and apoptosis, which might mediate increased toxicity²⁴. It has been established that a defect in mismatch repair is associated with resistance to many DNA damaging anti-cancer agents, such as mono- and bi-functional alkylators and antimetabolites^{7,23,25}. It should be noted that mismatch repair acts directly at replication forks and can therefore not prevent them from encountering damage.

Collapse of replication forks during DNA synthesis can be avoided by bypassing DNA lesions in a process called *translesion synthesis*^{26,27}. This process is carried out by switching the regular polymerases epsilon and delta, responsible for leading and lagging strand synthesis respectively^{28,29}, to polymerases with different substrate specificities, thus enabling them to bypass different types of damaged bases³⁰.

Once replication forks stall or collapse upon encountering DNA damage other repair pathways are required to permit resumption of replication. Collapsed replication forks are recognised by the checkpoint machinery, which will in turn trigger cell cycle arrest¹², DNA repair³¹ or cell death through apoptosis or senescence³²⁻³⁴. Although we know very little of the nature of replication lesions, there is an increasing body of information concerning pathways that repair them. *Homologous recombination* plays a central role in the repair of most replication lesions formed by anti-cancer drugs^{5,6,15,35}. There are several ways by which homologous recombination is utilised to restart replication. The sequence identity between two newly synthesised DNA molecules can be used to restart replication behind the replication block. Also, recombination can be used to bypass DNA lesions, in a process called template switching (see³⁶ for details). Other repair pathways active at replication forks involve the *Fanconi anaemia associated repair*³⁷, *endonuclease-mediated repair*, such as mediated by the Mus81 endonuclease³⁸,

and *RecQ-mediated repair*, involving DNA helicases such as BLM³⁹, WRN^{40,41} and other members of the RecQ family of helicases⁴². Several of the proteins in these pathways have been found to be directly linked with homologous recombination⁴³ or the resolution of recombination products such as Holliday junctions^{39,41,44,45}. However, cells that are defective in these pathways show distinct differences from recombination defective cells, indicating that they represent different but overlapping repair pathways⁴⁶.

Cells defective in a specific DNA repair pathway exhibit sensitivity to drugs producing DNA lesions that are normally repaired by this pathway. This sensitivity has been exploited to isolate hamster cell lines showing hypersensitivity to anti-cancer drugs (e.g. etoposide, mitomycin C) and ionizing radiation, and also to allow cloning of genes involved in DNA repair⁴⁷. The DNA repair pathways involved in the repair of damage caused by various anti-cancer agents are summarised in Figure 1. These DNA repair pathways are often up-regulated in tumour cells, resulting in resistance to chemotherapeutic drugs⁴⁸. Importantly, these DNA repair pathways can be inhibited pharmacologically to potentially increase the efficacy or specificity of anti-cancer agents (see below).

Current DNA repair inhibitors for cancer treatment

The basic understanding of DNA repair mechanisms, from the principles of the DNA lesions created and the pathways required to repair these lesions, has greatly increased during the past years. This permits a rational combination of cytotoxic agents and inhibitors of DNA repair to enhance tumour killing. Specific inhibitors of DNA repair that have been developed as clinical agents are discussed in this section (see Figure 2).

Sensitisers to alkylating agents. Despite the adverse side effects caused by alkylating agents on bone marrow and other normal tissues, drugs such as cyclophosphamide, ifosfamide, chlorambucil, melphalan and dacarbazine remain some of the most commonly prescribed chemotherapies in adults and children with various solid and haematological malignancies, particularly in multi-agent regimes combined with anthracyclines and steroids. More recently, a DNA alkylator and methylator developed in the 1980s, temozolomide (an oral prodrug which crosses the blood brain barrier) has

changed clinical practice in the treatment of high grade gliomas in adults and children^{49,50}. The combination of PARP1 inhibition and temozolomide is currently in several clinical trials (see Figure 2). The rationale for this treatment strategy is that inhibition of PARP retards the repair of an intermediate damage lesion, the apurinic site, induced by temozolomide. However, this intermediate is not generally regarded as a major contributor to the cytotoxicity induced by temozolomide in the absence of PARP inhibition, as they are promptly removed by base excision repair in cells with abundant functional PARP1. The success of the treatment rationale adopted by current clinical trials of GPI-21016 (Guilford Pharmaceuticals, Baltimore, MD), INO-1001 (Inotek Pharmaceuticals, Beverly, MA) and AG014699 (Pfizer GRD, La Jolla, CA) therefore depends on the overall biological role of and necessity for PARP in cancer cells trying to repair this type of damage.

Another class of agents currently being tested in clinical trials in combination with temozolomide therapy consists of the pseudosubstrates for MGMT. The lead compounds in this class have been O(6)-benzylguanine and lomeguatrib (AstraZeneca, Lund, Sweden), the latter also known as O(6)-(4-bromophenyl)guanine or PaTrin-2. Resistance to O(6-)alkylating agents can be overcome in preclinical models by depletion of MGMT⁵¹ and a relationship exists between MGMT activity and resistance to chloroethylating nitrosoureas and methylating agents in tumour cells grown in vitro and in xenograft models (reviewed in⁵²). O(6)-benzylguanine and lomeguatrib have recently been tested in phase I-II clinical trials and biologically effective doses have been established for both agents⁵³. However, results obtained so far indicate that, when used in combination with cytotoxic chemotherapy, myelosuppression is significantly enhanced, necessitating significant reductions in the doses of alkylating agents prescribed from those used in standard chemotherapy. On account of this lack of selectivity for malignant tissue versus normal bone marrow, no improvement in the *therapeutic index* has so far been demonstrated in clinical trials of these agents.

Platinum chemotherapies. Cisplatin, carboplatin and oxaliplatin have become three of the most commonly prescribed chemotherapeutic drugs used to treat solid cancers in patients⁵⁴. Platinum resistance, either intrinsic or acquired during cyclical treatment, is a

major clinical problem since additional agents that can be added to therapy in order to circumvent tumour resistance do not currently exist.

Currently, platinum chemotherapy is being tested with PARP inhibition in 2 clinical trials (Figure 2). The rationale for combining PARP inhibition with platinum chemotherapy is based on preclinical observations that PARP inhibitors preferentially kill neoplastic cells and induce complete or partial regression of a wide variety of human tumor xenografts in nude mice treated with platinum chemotherapy⁵⁵⁻⁵⁷. For example, ABT-888 (Abbott Laboratories, Chicago, IL), a potent inhibitor of PARP-1 and PARP-2, has been shown to potentiate regression of established tumours induced by temozolomide, cisplatin, carboplatin, or cyclophosphamide therapy in rodent orthotopic and xenograft models⁵⁸. In monotherapy, ABT-888 exhibits no significant anticancer activity in these preclinical models.

DNA demethylating agents such as 2'-deoxy-5-azacytidine (decitabine; MGI Pharma, Bloomington, MN) have been combined with cisplatin or carboplatin to reverse drug resistance caused by hypermethylation silencing of mismatch repair genes. The toxicity of agents such as cisplatin depends at least partly on functional mismatch repair (Figure 2). Preclinical data from xenograft models and translational studies from drug-resistant cells and tissues that are mismatch repair deficient owing to *MLH1* hypermethylation have demonstrated increased chemotherapeutic efficacy when a demethylating agent is combined with platinum chemotherapy^{59,60}. Decitabine is currently being tested in combination with carboplatin in a phase II clinical trial in patients with ovarian cancer.

Attenuators of checkpoint signalling. An alternative approach to modulate DNA repair activity and potentially improving therapeutic index is to interfere with cell cycle checkpoint signalling. XL844 (EXEL-9844) is a small-molecule inhibitor of the checkpoint kinases 1 and 2 (Chk1 and Chk2). It causes inhibition of cell cycle arrest, progressive DNA damage, inhibition of DNA repair, and, ultimately, tumour cell apoptosis in cancer cells grown *in vitro*⁶¹. XL844 is currently being tested in a clinical trial in combination with the deoxycytidine analogue, gemcitabine, which normally

causes cell cycle arrest and apoptosis by incorporation into DNA. The treatment efficacy of the inhibitor of ATM kinase, KU55933 (AstraZeneca, Lund, Sweden), is currently in late preclinical development.

Radiosensitisers. DNA-dependent protein kinase (DNA-PK) is highly important for DSB repair by non-homologous end joining/NHEJ following ionizing radiation, and cells defective in DNA-PK are highly sensitive to ionizing radiation⁶². Wortmannin is a fungal product that irreversibly inhibits PI-3 protein kinases, such as DNA-PK, at low nanomolar concentrations, resulting in antiproliferative effects and radiosensitisation in preclinical models⁶³. Unfortunately, it has been found to be unsuitable for clinical applications due to its inherent toxicity and instability in cells⁶⁴. Other small molecule inhibitors of DNA-PK have been synthesised which reversibly inhibit the kinase activity at low micromolar concentrations, and these are currently in transition from late preclinical development to early clinical trials. In particular, NU7441 (AstraZeneca, Lund, Sweden), has demonstrated chemosensitization of topoisomerase II poisons and radiosensitization in a manner consistent with DNA-PKcs inhibition⁶⁵.

DNA repair inhibitors as single agent treatment for DNA repair defective cancer

As discussed above, most of the current small molecule inhibitors of DNA repair have so far been tested in early clinical trials as sensitisers of tumour cells to chemotherapy. However, DNA damage also occurs spontaneously in cells in the absence of treatments and DNA repair pathways are therefore essential for the survival of untreated cells. As many cancers are defective in DNA damage response and repair pathways (Table 1), *synthetic lethal* interactions can be utilised to advocate DNA repair inhibitors as monotherapy (Figure 3). DNA repair is an ideal target for inhibition in cancer cells, as the inhibitors should be exclusively toxic to cancer cells and therefore be associated with minimal side effects for patients (see BOX1 for a summary of advantages and limitations with DNA repair inhibitors as single treatment).

Indeed, DNA repair inhibitors have been demonstrated to work as single agents to treat cancer, particularly in DNA repair defective tumours. The most notable example so far is a novel treatment for inherited breast and ovarian cancers that arise from cells

which have lost the wild-type copy of the *BRCA1* or *BRCA2* genes^{66,67}. *BRCA1*- and *BRCA2*-mutated cells are defective in homologous recombination repair^{68,69} and show extensive replication-associated lesions^{70,71}. These recombination defective cells are 100-1000 fold more sensitive to PARP inhibitors used as monotherapy than are the heterozygote or the wild-type cell lines, indicating the potential to be exploited to specifically treat *BRCA1* or *BRCA2* defective tumours^{66,67}. The molecular explanation for this extreme sensitivity is the overlapping roles of DNA single strand break (SSB) repair, which is dependent on PARP1⁷², and homologous recombination in repair at replication forks^{67,73,74}. Translation of this hypothesis has led to phase II clinical trials of monotherapy using the PARP inhibitor, AZD2281 (AstraZeneca, Lund, Sweden), currently recruiting patients with breast and ovarian cancer who harbour mutations in *BRCA1* or *BRCA2* genes. A separate phase II trial with the PARP-1 inhibitor AG014699 (Pfizer GRD, La Jolla, CA) is due to open to recruitment in the near future in known carriers of *BRCA1* or *BRCA2* mutations with locally advanced or metastatic breast or ovarian cancers.

Another synthetic lethal interaction has recently been discovered between the Fanconi anaemia repair pathway and the ATM checkpoint kinase⁷⁵ by the demonstration that two pancreatic tumour lines defective in the Fanconi anaemia pathway were more sensitive to the ATM inhibitor, KU-55933, than isogenic control lines. This finding provides a rationale to explore ATM inhibitors in the treatment of Fanconi anaemia repair-defective pancreatic cancer.

Mutations in DNA damage response and repair pathways are commonly associated with cancer (Table 1). Thus, it should be straightforward to exploit DNA repair inhibitors for the treatment of tumours carrying specific defects in DNA repair or damage signalling. We have compiled a list of reported cancer mutations in DNA repair genes and present synthetic lethal interactions demonstrated in *S. cerevisiae* (Table I). Proteins encoded by the synthetic lethal-interacting genes may represent good targets for specific treatment of cancers carrying a mutation in DNA repair genes.

Reliable *biomarkers* are critical for selection of patients that will respond to treatments in clinical trials. This is particularly important for treatments with DNA repair

inhibitors that exploit specific cancer defects for treatments, as cancers in patients without the DNA repair or damage response defect will not respond to treatment. Thus, the lack of reliable assays to measure biomarkers in accessible malignant tissues is an important barrier to the success of DNA repair inhibitors in the clinic. The most reliable markers are likely to be those that identify loss of specific post-translational modifications present in the DNA damage response and repair pathways, or upregulation of the activity of the targeted pathway (Figure 3).

Exploiting tumour specific replication stress for targeted cancer treatment

Current chemotherapy clearly proves that production of excessive replication lesions represents a highly successful means of killing cancer cells. It has been observed that tumour cells themselves exhibit a high level of endogenous replication lesions that result in genetic instability^{33,76}. Ideally, DNA repair inhibitors could be used to impair the repair of replication lesions present in tumour cells and convert them into fatal replication lesions that specifically kill cancer cells.

Oncogene-induced replication stress. The transformation of normal cells to a cancerous state is often initiated by the activation of oncogenes, which provide excessive growth signals⁷⁷. Oncogene-induced growth signals often mimic the growth signals that are used by the body to transfer cells from quiescent into proliferative states. Early on during neoplastic transformation, the pre-cancerous cells are often recognised by checkpoint proteins (e.g. p53, Chk2), which stop cell proliferation by initiating apoptosis or senescence^{78,79}, cell inactivating processes termed the tumour barrier⁸⁰. It was recently shown that oncogene activation induces replication-associated DNA lesions, and that these lesions are responsible for triggering the cell cycle checkpoint response that activates the tumour barrier^{33,34,81,82} (Figure 4).

Genes encoding proteins in the checkpoint pathways (e.g. the p53 pathway) are often mutated during cancer development⁸³, allowing cells to evade the tumour barrier and continue to proliferate (Figure 4). A key feature of cancer cells which express oncogenes and have managed to evade the tumour barrier, is that they have a higher level of endogenous replication-associated lesions than normal cells. This in turn contributes

to genetic instability⁸⁴ that will assist the tumour to induce the genetic changes required for continued transformation to malignancy⁷⁶. More importantly, the replication lesions caused by oncogene activation resemble those produced by anti-cancer treatments³³ which need to be repaired for the cancer cells to survive. We therefore suggest that future DNA repair inhibitors should be used to make existing cancer-specific replication lesions more toxic, resulting in fatal replication lesions selectively killing oncogene-expressing cancer cells.

Hypoxia-associated replication stress. More advanced cancers are exposed to another source of replication stress, owing to the tumour microenvironment. Tumours are often *hypoxic*, which have been shown to disrupt DNA synthesis⁸⁵. These conditions cause replication lesions that activate the ATM/ATR mediated checkpoint response⁸⁶⁻⁸⁸. Furthermore, DNA repair is down-regulated in hypoxic cells⁸⁹, which cumulatively contributes to the genetic instability observed in these cells^{90,91}. In this case, inhibitors of the checkpoint response might be more efficient than inhibitors of DNA repair⁹².

In summary, cancer cells are potentially exposed to unusually high levels of replication stress and endogenous DNA damage during cancer development. A future challenge will be to characterise forms of replication lesions occurring during different stages of carcinogenesis, which may be exploited for therapy.

Conclusions

The potential of DNA repair inhibitors in future cancer therapy is starting to be realised. Although selective inhibition of DNA repair pathways can be used to enhance current chemotherapy and radiotherapy, the most attractive use of DNA repair inhibitors may be in utilising cancer defects for more selective cell killing. DNA repair inhibitors that exploit tumour mutations in DNA repair pathways to convert spontaneous DNA lesions into fatal replication lesions may represent the most straightforward means to find selective treatments. This type of therapy is highly advantageous when compared to current chemotherapy as it is likely to produce minimal side effects whilst resulting in highly toxic replication lesions that will actively trigger cell death in cancer cells. A

potential limitation of this approach is that it is likely confined to DNA repair-defective tumours and that resistance mechanisms may develop. A more challenging treatment strategy is the inhibition of the repair of tumour-specific replication lesions and conversion of these into fatal lesions. Replication stress appears to be present in a majority of tumours, during at least one stage of carcinogenesis. Thus, the conversion of replication stress into fatal replication lesions could potentially be used to target a wide range of tumours. As we are still unaware of the exact nature of the replication lesions formed by many traditional chemotherapies, there is still considerable work to be done in characterising tumour-specific lesions to target cancers. Basic research into understanding the nature of toxic replication lesions as well as obtaining a more complete picture of all DNA repair pathways and their interplay is critical for the future of DNA repair inhibitors as single agents in cancer therapy.

Acknowledgments

We would like to thank members of the Radiation Oncology and Biology laboratory for helpful comments and the Medical Research Council (T.H.) and Cancer Research UK (R.S.) for financial support. We recognize that we were unable to cover all aspects of DNA repair in cancer in this review. We apologize to those that we have been unable to reference owing to space constraints.

BOX 1. Advantages and limitations using DNA repair inhibitors as single agents in treatment of cancers:

- (1) DNA repair inhibitors can exploit tumour-specific defects in checkpoint signalling and DNA repair to convert endogenous DNA lesions into fatal replication lesions that selectively kill tumour cells.
- (2) A general problem for novel cancer therapies is that they are not sufficiently efficient to replace current therapy. As a result many enzyme inhibitors, that are not targeting DNA repair, have failed at the phase III or IV stage during clinical trials owing to a general lack of efficacy. Inhibition of DNA repair amplifies toxic replication-associated DNA lesions that directly result in cell death. DNA repair inhibitors should therefore be highly efficient at killing tumours.

- (3) Extensive cross-talk between DNA repair pathways minimizes side effects in normal cells during inhibition of a single DNA repair pathway.
- (4) Tumour inactivation of DNA damage signalling and DNA repair are often relatively early events during carcinogenesis, suggesting that non-toxic DNA repair inhibitors may be considered in the treatment of patients with pre-malignant or early neoplastic lesions (e.g. ductal carcinoma-in-situ in patients with BRCA1 and BRCA2 inherited breast and ovarian cancer; intestinal lesions in patients with hMLH1 and hMSH2 hereditary non-polyposis colorectal cancer).
- (5) Extensive crosstalk between DNA repair pathways likely results in acquisition of resistance mechanisms in tumours, which is a limitation for killing late stage tumours.

Figure 1. Overview of DNA repair pathways involved in repairing toxic DNA lesions formed by cancer treatments. DNA damaging agents used in cancer treatment induce a diverse spectrum of toxic DNA lesions. These lesions are recognised by a variety of DNA repair pathways which are lesion-specific but highly overlapping. **(A)** Ionising radiation and radiomimetic drugs are the only agents to directly induce double strand breaks (DSBs), which are toxic independently of replication, and predominantly repaired by non-homologous end joining. **(B)** Mono- and **(C)** bi-functional alkylators induce DNA base modifications, which interfere with DNA synthesis and are processed into toxic lesions in a mismatch repair dependent manner. The base and nucleotide excision repair pathways are, together with alkyltransferases, major repair pathways, whereas other repair pathways repair toxic replication lesions, such as those produced following interstrand crosslinks. **(D)** Anti-metabolites interfere with nucleotide metabolism and DNA synthesis, causing mismatch repair mediated, but poorly characterised replication lesions. The repair pathways involved in repair of anti-metabolite-induced lesions are, apart from base excision repair, poorly characterised. **(E)** Topoisomerase inhibitors trap topoisomerase I or II in transient cleavage complexes with DNA, thus creating indirect DNA breaks and interfering with replication. **(F)** Replication inhibitors induce replication fork stalling and collapse, resulting in indirect DSBs. The relative contributions of the major repair pathways to the respective types of DNA damage outlined are indicated by the sizes of the boxes. Abbreviations used: AT, alkyltransferases; BER, base excision repair; O₂G, DNA dioxygenases;

ENDO, endonuclease-mediated repair; FA, Fanconi anaemia-mediated repair; HR, homologous recombination; NER, nucleotide excision repair; NHEJ, non-homologous end joining; RecQ, RecQ-mediated repair; SSBR, DNA single-strand break repair; TLS, trans lesion synthesis.

Figure 2. Ongoing clinical trials of small molecule inhibitors of the DNA damage response and related signalling pathways. The recent or current stage of development of clinical trials is indicated for individual compounds, which are grouped by molecular target. For details of specific agents, see main text.

Figure 3. Synthetic lethal interactions to identify molecular targets and biomarkers for inhibitors of DNA repair. Proteins that interact are often within functional modules involved in catalysing checkpoint and repair pathways. A mutation in a single tumour suppressor gene **(A)** normally impairs the full functional module. Such loss of a checkpoint or repair pathway results in genetic instability, which would lead to cell death unless a DNA repair salvage pathway **(B)** is upregulated. As the two pathways collaborate to maintain survival, targeting pathway B in monotherapy will specifically kill tumour cells and be non-toxic to normal cells, as they can use pathway A for survival. An additional mutation **(C)** upstream of the targeted pathway B causes complete resistance to the treatment. For instance, if pathways A+B are required for resolving a certain type of recombination intermediate, a mutation in a protein C involved in the formation of this recombination intermediate (e.g. BRCA2, which is involved in early stages of recombination) will make pathways A+B redundant. In the absence of C, the **(D)+(E)** pathways would be used to rescue replication, independently of recombination. A novel monotherapy targeting pathways D+E would then be needed to kill B resistant tumour cells. Proteins are indicated by circles, protein interactions with red lines, functional modules with blue boxes. Black boxes indicate mutated pathways. Red boxes indicate salvage DNA repair pathways.

Figure 4. Oncogene-induced replication stress as a target for DNA repair inhibitors. Oncogene expression results in unscheduled replication origin firing, which decreases the distance between origins³⁴ and causes replication forks to collapse³³. Such replication lesions activate the tumour barrier, including the ATM-mediated checkpoint pathway, to trigger apoptosis or senescence and to prevent tumour outgrowth^{81,82}. Inactivation of checkpoint pathways (for instance by *p53* mutation) results in cancer cells evading apoptosis and senescence, which allows continued proliferation. Collapsed replication forks need to be repaired to allow cell survival. Tumour defects in checkpoint and repair pathways will result in collapsed forks that are often incorrectly repaired, resulting in

genetic instability that will drive future mutations. Here, we suggest that tumour-specific replication lesions can be converted into fatal replication lesions through inhibition of DNA repair. Such therapy is likely to be tumour specific as normal cells should not have oncogene-induced replication stress.

Definitions

Alkylating agents

Electrophilic compounds that are reactive either directly or following metabolism and bind covalently to electron rich atoms in DNA bases (i.e. oxygen and nitrogen).

Alkyltransferases

Class of enzymes that directly reverse DNA base modifications induced by alkylating agents by transferring the alkyl group from the base on to the protein.

Antimetabolites

Compounds with similar chemical structures to nucleotide metabolites that interfere with nucleotide biosynthesis or are incorporated into DNA.

Base excision repair

A repair pathway that replaces missing or modified DNA bases, such as those produced by alkylating agents or in spontaneously degraded DNA, with the correct DNA base.

Biomarkers

A molecule or substance whose detection indicates a particular disease state or treatment response.

DNA-dioxygenases

Class of enzymes that directly reverse DNA base methylations via an oxidation mechanism. The human DNA-dioxygenase ABH2 is believed to act at replication forks.

Endonuclease-mediated repair

A repair pathway that introduces a DNA single-strand break in a DNA structure to facilitate continuous repair.

Fanconi anemia-associated repair

A repair pathway with largely unknown function active at damaged replication forks.

Homologous recombination

A process that can copy a DNA sequence from an intact DNA molecule (often the newly synthesised sister chromatid) to repair or bypass replication lesions.

Hypoxia

A shortage of oxygen. In cancer this is often the result of insufficient vasculature.

Mismatch repair

Acts during DNA replication to correct base-pairing errors made by the DNA polymerases.

Non-homologous end joining

Connects and re-seals the two ends of a DNA double strand break without the need for sequence homology between the ends.

Nucleotide excision repair

Removes large DNA adducts or base modifications which distort the double helix and use the opposite strand as template for repair.

RecQ-mediated repair

A repair pathway that unwinds complex DNA structure to facilitate repair.

Synthetic lethality

Genetic phenomenon where the combination of two non-lethal mutations results in lethality because the second mutation inactivates a backup mechanism allowing for tolerance of the first mutation and vice versa.

Trans-lesion synthesis

Mechanism during DNA replication where the standard DNA polymerase is temporarily exchanged for a specialised polymerase which can synthesise DNA across base damage on the template strand.

Therapeutic index

The therapeutic index describes the ability of a treatment strategy to kill cancer cells in preference to cells in normal tissues.

Table I. Synthetic lethal interactions in DNA repair and cell cycle checkpoint genes implicated in cancer. Abbreviations used: BER, base excision repair; FA, Fanconi anaemia-mediated repair; HR, homologous recombination; NER, nucleotide excision repair; NHEJ, non-homologous end joining; MMR, mismatch repair; RecQ, RecQ-mediated repair

Pathway	Protein	Syndrome	Primary cancers	Biomarker	Synthetic lethality	Homolog <i>S. cerevisiae</i>	Synthetic lethality <i>S. cerevisiae</i> ⁹³⁻¹⁷²
HR							
	BRCA1		breast, ovarian ¹⁷³		PARP1 ⁶⁶	-	-
	BRCA2	Fanconi's anemia	breast, ovarian ¹⁷⁴		PARP1 ^{66,67}	-	-
	RAD54B		non-Hodgkin lymphoma, colon cancer ¹⁷⁵			rdh54	cla4, bim1, rad27, ctf4, ctf8, ctf18, dcc1, tof1, pol32, srs2, ulp1, elg1, nup133, nup120, ccr4, cik1, ctk1, ctk2, ctk3, lsm7, pop2, mnr4, rrm3, sod1, swi6, tsa1.
	RAD51B		lipoma, uterine leiomyoma ¹⁷⁶			rad51	rad27, ctf4, ctf8, ctf18, tof1, pol32, elg1, orc2, orc5, nup133, nup120, ctk1, ctk2, ctk3, mnr4, sod1, swi6, tsa1, ubc9
	CtIP		colorectal cancer ¹⁷⁷			sae2	sgs1, rad27, rrm3, dia2, pph3
NHEJ							
	MRE11	Ataxia-telangiectasia-like disorder (ATLD)	colorectal cancer ¹⁷⁸			mre11	rad27, bim1, ctf4, ctf18, dcc1, top1, chs1, chs5, kre9, rrm3, sap30, elg1, srs2, yku80, ulp1, xrs2, rad50, nup133, nup120, hsp82, orc6, cdc6, ccr4, dia2, ccs1, cik1, ctk1, ctk2, ctk3, mdm12, pop2, mnr4, sod1, swi6, tsa1, vid22, pph3, gcs1, dna2
	LIG4	LIG4 syndrome	Leukemia ¹⁷⁹			lig4	-
	Artemis	Omenn syndrome	Lymphoma ¹⁸⁰			pso2	-
MMR							
	hMSH2		hereditary nonpolyposis colorectal cancer (HNPCC) ¹⁸¹	microsatellite instability (MSI)		msh2	pol3
	hMLH1		HNPCC ¹⁸²	MSI		mlh1	cdc7, pol3, mms4
	hMSH6		HNPCC ¹⁸³	MSI		msh6	pol3
	hPMS1		HNPCC ¹⁸⁴	MSI		pms1	pol3
	hPMS2		HNPCC ¹⁸⁴	MSI		pms1	pol3
	hMLH3		HNPCC ¹⁸⁵	MSI		mlh3	none
RecQ homologues							
	BLM	Bloom's syndrome	Various ¹⁸⁶	Elevated SCE		sgs1	srs2, dcc1, mrc1, cdc7, cdc8, hst3, dna2, est2, slx5, slx8, wss1, yku70, rnr202, elg1, ccs1, nup133, nup120, dia2, slx1, sae2, slx4, pol31, siz1, nfi1, asf1, mnr1, rrm3, mgs1, csm3, esc2, rtt107, top1, swe1, pub1, rpl24a, sis2, sod1, pby1, ctf18, ctf4, mms4, mus81, rad50
	WRN	Werner's syndrome	Various ¹⁸⁷			sgs1	srs2, dcc1, mrc1, cdc7, cdc8, hst3, dna2, est2, slx5, slx8, wss1, yku70, rnr202, elg1, ccs1, nup133, nup120, dia2, slx1, sae2, slx4, pol31, siz1, nfi1, asf1, mnr1, rrm3, mgs1, csm3, esc2, rtt107, top1, swe1, pub1, rpl24a, sis2,

							sod1, pby1, ctf18, ctf4, mms4, mus81, rad50
	RECQL4	Rothmund-Thomson syndrome	skin basal and squamous cell, osteosarcoma ¹⁸⁷			sgs1	srs2, dcc1, mrc1, cdc7, cdc8, hst3, dna2, est2, slx5, slx8, wss1, yku70, rnr202, elg1, ccs1, nup133, nup120, dia2, slx1, sae2, slx4, pol31, siz1, nfi1, asf1, rnr1, rrm3, mgs1, csm3, esc2, rtt107, top1, swe1, pub1, rpl24a, sis2, sod1, pby1, ctf18, ctf4, mms4, mus81, rad50
Damage signaling							
	ATM	Ataxia-telangiectasia	Leukemia ¹⁸⁸		PARP1 ^{189,190} FANC ⁷⁵	tel1	mec1, dna2
	NBS1	Nijmegen breakage syndrome	Various ¹⁹¹			xrs2	ctk2, ctk3, dia2, mdm12, nup133, pop2, rnr4, sod1, swi6, tsa1, vid22, rad27, cdc73, kar3, mrc1, pol32, cdc45, mms4, srs2, rrm3, mre11, elg1, nup120, orc6, cdc6, ccr4, ccs1, mms22, cik1, ctk1
	p53	Li-Fraumeni	Various ¹⁹²			-	-
	CHEK2	Li-Fraumeni	Various ¹⁹³			dun1/rad53	chk1, bmh1, nat1, rad9, ubx7, bsc4, cdc7, mec1, pol3, clb5, rnr4, rmi1, elg1, orc6, cdc6, ccr4, cdc73, clb5, ctk3, eaf5, htz1, ies2, lsm1, mrc1, npl3, pep3, pep5, pop2, puf4, rad27, snf8, eaf1, vps34, yaf9, dia2, dbf4, pap2
NER							
	XPA	Xeroderma pigmentosum (XP)	skin cancers ¹⁹⁴			rad14	gmh1, ntg1, ntg2
	XPB	XP, Cockayne syndrome (CS)	skin cancers ¹⁹⁵			rad25	rad3, sti1
	XPC	XP	skin cancers ¹⁹⁶			rad4	ric1, ypt6, csm3, hsp82, ctf4, ctf18, dcc1, tof1, rad23, mad2
	XPD	XP, CS, Trichothiodystrophy	skin cancers ¹⁹⁷			rad3	act1, nip7, nop1, rad50, rad52, kin28, ssl2
	XPE/DDB2	XP	basal cell carcinomas ¹⁹⁸			-	
	XPF	XP	skin cancers ¹⁹⁹			rad1	ntg1, ntg2, apn2, apn2, rad27, tdp1, mec1
	XPG	XP	squamous cell carcinoma, head and neck ²⁰⁰			rad2	none
	XPV	XP	skin cancers ²⁰¹			rad30	msh6, pms1
	ERCC1	cerebro-oculo-facio-skeletal syndrome	squamous cell carcinoma, head and neck ²⁰⁰			rad10	cla4, gim4, mec1, mad2, apn1, apn2
Crosslink repair							
	FANCA	Fanconi's anemia	Various ²⁰²	FANC D2 Ubiquitination ⁷⁵	ATM ⁷⁵	-	-
	FANCB	Fanconi's anemia	Various ²⁰²			-	-
	FANCC	Fanconi's anemia	Various ²⁰²	FANC D2 Ubiquitination ⁷⁵	ATM ⁷⁵	-	-
	FANCD2	Fanconi's anemia	Various ²⁰²		ATM ⁷⁵	-	-
	FANCE	Fanconi's anemia	Various ²⁰²	FANC D2 Ubiquitination ⁷⁵	ATM ⁷⁵	-	-

	FANCF	Fanconi's anemia	Various ²⁰²			-	-
	FANCG/ XRCC9	Fanconi's anemia	Various ²⁰²	FANCD2 Ubiquitination ⁷⁵	ATM ⁷⁵	-	-
	FANCI	Fanconi's anemia	Various ²⁰²			-	-
	FANCL	Fanconi's anemia	Various ²⁰²			-	-
BER							
	PolB		Various ²⁰³			pol4	-
	FEN1		Various ²⁰⁴			rad27	lcd1, sgs1, mms4, mus81, sae2, rad50, srs2, ddc1, cac2, exo1, mre11, rad6, rad9, rad17, rad24, rad52, xrs2, ctf4, rpl27a, rps30b, doc1, esc2, hst1, hpc2, csm3, ccs1, sis2, sod1, ydj1, hst3, ylr352w, ypr116w, bud27, ctf18, dcc1, chl1, mrc1, tof1, pol32, cdc8, exo1, mre11, pol3, rad1, cln1, cln2, rad51, rad53, rad54, rad55, rad57, rad59, rfc1, xrs2, ulp1, elg1, rnh201, rnh202, rnh203, mec3, rad6, slx8, slx9, top3, asf1, rlf2, pap2, rpn4, doa4, bro1, grr1, nup84, nup120, nup133, nat3, sfp1, thp1, tef4, aat2, gas1, pep5, pmr1, ume6, bre1, slx5, ige1, mec1, mec3, mms22, arp8, dia2, hur1, lrs4, lsm7, lte1, npl3, rmd9, rtf1, uaf30, eaf1, sae2, pph3, ulp1, nup60

REFERENCES

1. Hsiang, Y. H., Lihou, M. G. & Liu, L. F. Arrest of replication forks by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin. *Cancer Res* **49**, 5077-82. (1989).
2. Markovits, J. et al. Topoisomerase II-mediated DNA breaks and cytotoxicity in relation to cell proliferation and the cell cycle in NIH 3T3 fibroblasts and L1210 leukemia cells. *Cancer Res* **47**, 2050-5 (1987).
3. Ikegami, S. et al. Aphidicolin prevents mitotic cell division by interfering with the activity of DNA polymerase-alpha. *Nature* **275**, 458-60. (1978).
4. Bianchi, V., Pontis, E. & Reichard, P. Changes of deoxyribonucleoside triphosphate pools induced by hydroxyurea and their relation to DNA synthesis. *J Biol Chem* **261**, 16037-42. (1986).
5. Lundin, C. et al. Different roles for nonhomologous end joining and homologous recombination following replication arrest in mammalian cells. *Mol Cell Biol* **22**, 5869-78. (2002).
6. Saintigny, Y. et al. Characterization of homologous recombination induced by replication inhibition in mammalian cells. *Embo J* **20**, 3861-70. (2001).
7. Swann, P. F. et al. Role of postreplicative DNA mismatch repair in the cytotoxic action of thioguanine. *Science* **273**, 1109-11. (1996).
8. Wang, J. C. Cellular roles of DNA topoisomerases: a molecular perspective. *Nat Rev Mol Cell Biol* **3**, 430-40. (2002).

9. Painter, R. B. & Cleaver, J. E. Repair replication in HeLa cells after large doses of x-irradiation. *Nature* **216**, 369-70 (1967).
10. Canman, C. E. et al. Activation of the ATM kinase by ionizing radiation and phosphorylation of p53. *Science* **281**, 1677-9. (1998).
11. Falck, J., Mailand, N., Syljuasen, R. G., Bartek, J. & Lukas, J. The ATM-Chk2-Cdc25A checkpoint pathway guards against radioresistant DNA synthesis. *Nature* **410**, 842-7. (2001).
12. Cliby, W. A. et al. Overexpression of a kinase-inactive ATR protein causes sensitivity to DNA-damaging agents and defects in cell cycle checkpoints. *Embo J* **17**, 159-69 (1998).
13. Taylor, A. M. et al. Ataxia telangiectasia: a human mutation with abnormal radiation sensitivity. *Nature* **258**, 427-9 (1975).
14. Sargent, R. G., Brenneman, M. A. & Wilson, J. H. Repair of site-specific double-strand breaks in a mammalian chromosome by homologous and illegitimate recombination. *Mol Cell Biol* **17**, 267-77. (1997).
15. Arnaudeau, C., Lundin, C. & Helleday, T. DNA double-strand breaks associated with replication forks are predominantly repaired by homologous recombination involving an exchange mechanism in mammalian cells. *J Mol Biol* **307**, 1235-45. (2001).
16. Sharma, R. A. & Dianov, G. L. Targeting base excision repair to improve cancer therapies. *Mol Aspects Med* **28**, 345-74 (2007).
17. Huang, J. C., Svoboda, D. L., Reardon, J. T. & Sancar, A. Human nucleotide excision nuclease removes thymine dimers from DNA by incising the 22nd phosphodiester bond 5' and the 6th phosphodiester bond 3' to the photodimer. *Proc Natl Acad Sci U S A* **89**, 3664-8 (1992).
18. Sugasawa, K. et al. A multistep damage recognition mechanism for global genomic nucleotide excision repair. *Genes Dev* **15**, 507-21 (2001).
19. Sedgwick, B. Repairing DNA-methylation damage. *Nat Rev Mol Cell Biol* **5**, 148-57 (2004).
20. Lindahl, T., Demple, B. & Robins, P. Suicide inactivation of the E. coli O6-methylguanine-DNA methyltransferase. *Embo J* **1**, 1359-63 (1982).
21. Duncan, T. et al. Reversal of DNA alkylation damage by two human dioxygenases. *Proc Natl Acad Sci U S A* **99**, 16660-5 (2002).
22. Erixon, K. & Ahnstrom, G. Single-strand breaks in DNA during repair of UV-induced damage in normal human and xeroderma pigmentosum cells as determined by alkaline DNA unwinding and hydroxylapatite chromatography: effects of hydroxyurea, 5-fluorodeoxyuridine and 1-beta-D-arabinofuranosylcytosine on the kinetics of repair. *Mutat Res* **59**, 257-71. (1979).
23. Karran, P. & Marinus, M. G. Mismatch correction at O6-methylguanine residues in E. coli DNA. *Nature* **296**, 868-9 (1982).
24. Yoshioka, K., Yoshioka, Y. & Hsieh, P. ATR kinase activation mediated by MutSalph and MutLalpha in response to cytotoxic O6-methylguanine adducts. *Mol Cell* **22**, 501-10 (2006).
25. Fram, R. J., Cusick, P. S., Wilson, J. M. & Marinus, M. G. Mismatch repair of cis-diamminedichloroplatinum(II)-induced DNA damage. *Mol Pharmacol* **28**, 51-5 (1985).

26. Masutani, C., Kusumoto, R., Iwai, S. & Hanaoka, F. Mechanisms of accurate translesion synthesis by human DNA polymerase *eta*. *Embo J* **19**, 3100-9 (2000).
27. Vaisman, A., Masutani, C., Hanaoka, F. & Chaney, S. G. Efficient translesion replication past oxaliplatin and cisplatin GpG adducts by human DNA polymerase *eta*. *Biochemistry* **39**, 4575-80 (2000).
28. Fukui, T. et al. Distinct roles of DNA polymerases delta and epsilon at the replication fork in *Xenopus* egg extracts. *Genes Cells* **9**, 179-91 (2004).
29. Pursell, Z. F., Isoz, I., Lundstrom, E. B., Johansson, E. & Kunkel, T. A. Yeast DNA polymerase epsilon participates in leading-strand DNA replication. *Science* **317**, 127-30 (2007).
30. Lehmann, A. R. Translesion synthesis in mammalian cells. *Exp Cell Res* **312**, 2673-6. (2006).
31. Sorensen, C. S. et al. The cell-cycle checkpoint kinase Chk1 is required for mammalian homologous recombination repair. *Nat Cell Biol* **7**, 195-201. (2005).
32. Kastan, M. B. & Bartek, J. Cell-cycle checkpoints and cancer. *Nature* **432**, 316-23. (2004).
33. Bartkova, J. et al. Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints. *Nature* **444**, 633-7. (2006).
34. Di Micco, R. et al. Oncogene-induced senescence is a DNA damage response triggered by DNA hyper-replication. *Nature* **444**, 638-42. (2006).
35. Arnaudeau, C., Tenorio Miranda, E., Jenssen, D. & Helleday, T. Inhibition of DNA synthesis is a potent mechanism by which cytostatic drugs induce homologous recombination in mammalian cells. *Mutat Res DNA repair* **461**, 221-8. (2000).
36. Helleday, T., Lo, J., van Gent, D. C. & Engelward, B. P. DNA double-strand break repair: From mechanistic understanding to cancer treatment. *DNA Repair (Amst)* **6**, 923-35 (2007).
37. Patel, K. J. & Joenje, H. Fanconi anemia and DNA replication repair. *DNA Repair (Amst)* **6**, 885-90 (2007).
38. Hanada, K. et al. The structure-specific endonuclease Mus81 contributes to replication restart by generating double-strand DNA breaks. *Nat Struct Mol Biol* (2007).
39. Karow, J. K., Constantinou, A., Li, J. L., West, S. C. & Hickson, I. D. The Bloom's syndrome gene product promotes branch migration of holliday junctions. *Proc Natl Acad Sci U S A* **97**, 6504-8. (2000).
40. Lebel, M., Spillare, E. A., Harris, C. C. & Leder, P. The Werner syndrome gene product co-purifies with the DNA replication complex and interacts with PCNA and topoisomerase I. *J Biol Chem* **274**, 37795-9 (1999).
41. Constantinou, A. et al. Werner's syndrome protein (WRN) migrates Holliday junctions and co-localizes with RPA upon replication arrest. *EMBO Rep* **1**, 80-4 (2000).
42. Wu, L. & Hickson, I. D. DNA helicases required for homologous recombination and repair of damaged replication forks. *Annu Rev Genet* **40**, 279-306 (2006).
43. Niedzwiedz, W. et al. The Fanconi anaemia gene FANCC promotes homologous recombination and error-prone DNA repair. *Mol Cell* **15**, 607-20 (2004).

44. Wu, L. & Hickson, I. D. The Bloom's syndrome helicase suppresses crossing over during homologous recombination. *Nature* **426**, 870-4. (2003).
45. Chen, X. B. et al. Human Mus81-associated endonuclease cleaves Holliday junctions in vitro. *Mol Cell* **8**, 1117-27. (2001).
46. Hinz, J. M., Nham, P. B., Urbin, S. S., Jones, I. M. & Thompson, L. H. Disparate contributions of the Fanconi anemia pathway and homologous recombination in preventing spontaneous mutagenesis. *Nucleic Acids Res* **35**, 3733-40 (2007).
47. Thompson, L. H. Strategies for cloning mammalian DNA repair genes. *Methods Mol Biol* **113**, 57-85 (1999).
48. Chabner, B. A. & Roberts, T. G., Jr. Timeline: Chemotherapy and the war on cancer. *Nat Rev Cancer* **5**, 65-72 (2005).
49. Stevens, M. F. et al. Antitumor activity and pharmacokinetics in mice of 8-carbamoyl-3-methyl-imidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one (CCRG 81045; M & B 39831), a novel drug with potential as an alternative to dacarbazine. *Cancer Res* **47**, 5846-52 (1987).
50. Stupp, R. et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. *N Engl J Med* **352**, 987-96 (2005).
51. Gerson, S. L., Berger, N. A., Arce, C., Petzold, S. J. & Willson, J. K. Modulation of nitrosourea resistance in human colon cancer by O6-methylguanine. *Biochem Pharmacol* **43**, 1101-7 (1992).
52. Middleton, M. R. & Margison, G. P. Improvement of chemotherapy efficacy by inactivation of a DNA-repair pathway. *Lancet Oncol* **4**, 37-44 (2003).
53. Ranson, M. et al. Lomeguatrib, a potent inhibitor of O6-alkylguanine-DNA-alkyltransferase: phase I safety, pharmacodynamic, and pharmacokinetic trial and evaluation in combination with temozolomide in patients with advanced solid tumors. *Clin Cancer Res* **12**, 1577-84 (2006).
54. Rosenberg, B., VanCamp, L., Trosko, J. E. & Mansour, V. H. Platinum compounds: a new class of potent antitumour agents. *Nature* **222**, 385-6 (1969).
55. Kubo, S. et al. Participation of poly(ADP-ribose) polymerase in the drug sensitivity in human lung cancer cell lines. *J Cancer Res Clin Oncol* **118**, 244-8 (1992).
56. Miknyoczki, S. J. et al. Chemopotentiation of temozolomide, irinotecan, and cisplatin activity by CEP-6800, a poly(ADP-ribose) polymerase inhibitor. *Mol Cancer Ther* **2**, 371-82 (2003).
57. Robins, H. I. et al. Phase I trial of intravenous thymidine and carboplatin in patients with advanced cancer. *J Clin Oncol* **17**, 2922-31 (1999).
58. Donawho, C. K. et al. ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models. *Clin Cancer Res* **13**, 2728-37 (2007).
59. Gifford, G., Paul, J., Vasey, P. A., Kaye, S. B. & Brown, R. The acquisition of hMLH1 methylation in plasma DNA after chemotherapy predicts poor survival for ovarian cancer patients. *Clin Cancer Res* **10**, 4420-6 (2004).
60. Plumb, J. A., Strathdee, G., Sludden, J., Kaye, S. B. & Brown, R. Reversal of drug resistance in human tumor xenografts by 2'-deoxy-5-azacytidine-induced demethylation of the hMLH1 gene promoter. *Cancer Res* **60**, 6039-44 (2000).

61. Matthews, D. J. et al. Pharmacological abrogation of S-phase checkpoint enhances the anti-tumor activity of gemcitabine in vivo. *Cell Cycle* **6**, 104-10 (2007).
62. Blunt, T. et al. Defective DNA-dependent protein kinase activity is linked to V(D)J recombination and DNA repair defects associated with the murine scid mutation. *Cell* **80**, 813-23. (1995).
63. Monfar, M. et al. Activation of pp70/85 S6 kinases in interleukin-2-responsive lymphoid cells is mediated by phosphatidylinositol 3-kinase and inhibited by cyclic AMP. *Mol Cell Biol* **15**, 326-37 (1995).
64. Wipf, P. & Halter, R. J. Chemistry and biology of wortmannin. *Org Biomol Chem* **3**, 2053-61 (2005).
65. Zhao, Y. et al. Preclinical evaluation of a potent novel DNA-dependent protein kinase inhibitor NU7441. *Cancer Res* **66**, 5354-62 (2006).
66. Farmer, H. et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. *Nature* **434**, 917-21. (2005).
67. Bryant, H. E. et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose)polymerase. *Nature* **434**, 913-7. (2005).
68. Moynahan, M. E., Chiu, J. W., Koller, B. H. & Jasin, M. Brca1 controls homology-directed DNA repair. *Mol Cell* **4**, 511-8. (1999).
69. Moynahan, M. E., Pierce, A. J. & Jasin, M. BRCA2 is required for homology-directed repair of chromosomal breaks. *Mol Cell* **7**, 263-72. (2001).
70. Patel, K. J. et al. Involvement of Brca2 in DNA repair. *Mol Cell* **1**, 347-57. (1998).
71. Lomonosov, M., Anand, S., Sangrithi, M., Davies, R. & Venkitaraman, A. R. Stabilization of stalled DNA replication forks by the BRCA2 breast cancer susceptibility protein. *Genes Dev* **17**, 3017-22. (2003).
72. Fisher, A., Hochegger, H., Takeda, S. & Caldecott, K. W. Poly (ADP-ribose) Polymerase-1 Accelerates Single-Strand Break Repair in Concert with Poly (ADP-ribose) Glycohydrolase. *Mol Cell Biol* (2007).
73. Helleday, T., Bryant, H. E. & Schultz, N. Poly(ADP-ribose) polymerase (PARP-1) in homologous recombination and as a target for cancer therapy. *Cell Cycle* **4**, 1176-8 (2005).
74. Schultz, N., Lopez, E., Saleh-Gohari, N. & Helleday, T. Poly(ADP-ribose) polymerase (PARP-1) has a controlling role in homologous recombination. *Nucleic Acids Res* **31**, 4959-64. (2003).
75. Kennedy, R. D. et al. Fanconi anemia pathway-deficient tumor cells are hypersensitive to inhibition of ataxia telangiectasia mutated. *J Clin Invest* **117**, 1440-9 (2007).
76. Lengauer, C., Kinzler, K. W. & Vogelstein, B. Genetic instabilities in human cancers. *Nature* **396**, 643-9. (1998).
77. Hanahan, D. & Weinberg, R. A. The hallmarks of cancer. *Cell* **100**, 57-70. (2000).
78. Schmitt, C. A. Senescence, apoptosis and therapy--cutting the lifelines of cancer. *Nat Rev Cancer* **3**, 286-95 (2003).
79. Braig, M. et al. Oncogene-induced senescence as an initial barrier in lymphoma development. *Nature* **436**, 660-5 (2005).

80. Kinzler, K. W. & Vogelstein, B. Cancer-susceptibility genes. Gatekeepers and caretakers. *Nature* **386**, 761-763. (1997).
81. Gorgoulis, V. G. et al. Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions. *Nature* **434**, 907-13. (2005).
82. Bartkova, J. et al. DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. *Nature* **434**, 864-70. (2005).
83. Vousden, K. H. & Lane, D. P. p53 in health and disease. *Nat Rev Mol Cell Biol* **8**, 275-83 (2007).
84. Mariani, B. D. & Schimke, R. T. Gene amplification in a single cell cycle in Chinese hamster ovary cells. *J Biol Chem* **259**, 1901-10 (1984).
85. Rambach, W. A., Cooper, J. A. & Alt, H. L. Effect of hypoxia on DNA synthesis in the bone marrow and spleen of the rat. *Science* **119**, 380-1 (1954).
86. Hammond, E. M., Denko, N. C., Dorie, M. J., Abraham, R. T. & Giaccia, A. J. Hypoxia links ATR and p53 through replication arrest. *Mol Cell Biol* **22**, 1834-43 (2002).
87. Hammond, E. M., Dorie, M. J. & Giaccia, A. J. ATR/ATM targets are phosphorylated by ATR in response to hypoxia and ATM in response to reoxygenation. *J Biol Chem* **278**, 12207-13 (2003).
88. Gibson, S. L., Bindra, R. S. & Glazer, P. M. Hypoxia-induced phosphorylation of Chk2 in an ataxia telangiectasia mutated-dependent manner. *Cancer Res* **65**, 10734-41 (2005).
89. Bindra, R. S., Crosby, M. E. & Glazer, P. M. Regulation of DNA repair in hypoxic cancer cells. *Cancer Metastasis Rev* **26**, 249-60 (2007).
90. Rockwell, S., Yuan, J., Peretz, S. & Glazer, P. M. Genomic instability in cancer. *Novartis Found Symp* **240**, 133-42; discussion 142-51 (2001).
91. Reynolds, T. Y., Rockwell, S. & Glazer, P. M. Genetic instability induced by the tumor microenvironment. *Cancer Res* **56**, 5754-7 (1996).
92. Hammond, E. M., Dorie, M. J. & Giaccia, A. J. Inhibition of ATR leads to increased sensitivity to hypoxia/reoxygenation. *Cancer Res* **64**, 6556-62 (2004).
93. Argueso, J. L. et al. Analysis of conditional mutations in the *Saccharomyces cerevisiae* MLH1 gene in mismatch repair and in meiotic crossing over. *Genetics* **160**, 909-21 (2002).
94. Bastin-Shanower, S. A., Fricke, W. M., Mullen, J. R. & Brill, S. J. The mechanism of Mus81-Mms4 cleavage site selection distinguishes it from the homologous endonuclease Rad1-Rad10. *Mol Cell Biol* **23**, 3487-96 (2003).
95. Bellaoui, M. et al. Elg1 forms an alternative RFC complex important for DNA replication and genome integrity. *Embo J* **22**, 4304-13 (2003).
96. Blake, D. et al. The F-box protein Dia2 overcomes replication impedence to promote genome stability in *Saccharomyces cerevisiae*. *Genetics* **174**, 1709-27 (2006).
97. Boiteux, S. & Guillet, M. Use of yeast for detection of endogenous abasic lesions, their source, and their repair. *Methods Enzymol* **408**, 79-91 (2006).
98. Dohrmann, P. R., Oshiro, G., Tecklenburg, M. & Sclafani, R. A. RAD53 regulates DBF4 independently of checkpoint function in *Saccharomyces cerevisiae*. *Genetics* **151**, 965-77 (1999).

99. Daniel, J. A., Keyes, B. E., Ng, Y. P., Freeman, C. O. & Burke, D. J. Diverse functions of spindle assembly checkpoint genes in *Saccharomyces cerevisiae*. *Genetics* **172**, 53-65 (2006).
100. Davierwala, A. P. et al. The synthetic genetic interaction spectrum of essential genes. *Nat Genet* **37**, 1147-52 (2005).
101. Debrauwere, H., Loeillet, S., Lin, W., Lopes, J. & Nicolas, A. Links between replication and recombination in *Saccharomyces cerevisiae*: a hypersensitive requirement for homologous recombination in the absence of Rad27 activity. *Proc Natl Acad Sci U S A* **98**, 8263-9 (2001).
102. Goehring, A. S. et al. Synthetic lethal analysis implicates Ste20p, a p21-activated protein kinase, in polarisome activation. *Mol Biol Cell* **14**, 1501-16 (2003).
103. Hwang, J. Y., Smith, S. & Myung, K. The Rad1-Rad10 complex promotes the production of gross chromosomal rearrangements from spontaneous DNA damage in *Saccharomyces cerevisiae*. *Genetics* **169**, 1927-37 (2005).
104. Ii, M. & Brill, S. J. Roles of SGS1, MUS81, and RAD51 in the repair of lagging-strand replication defects in *Saccharomyces cerevisiae*. *Curr Genet* **48**, 213-25 (2005).
105. Jin, Y. H. et al. The 3'-->5' exonuclease of DNA polymerase delta can substitute for the 5' flap endonuclease Rad27/Fen1 in processing Okazaki fragments and preventing genome instability. *Proc Natl Acad Sci U S A* **98**, 5122-7 (2001).
106. Kaliraman, V. & Brill, S. J. Role of SGS1 and SLX4 in maintaining rDNA structure in *Saccharomyces cerevisiae*. *Curr Genet* **41**, 389-400 (2002).
107. Karumbati, A. S. & Wilson, T. E. Abrogation of the Chk1-Pds1 checkpoint leads to tolerance of persistent single-strand breaks in *Saccharomyces cerevisiae*. *Genetics* **169**, 1833-44 (2005).
108. Keogh, M. C. et al. A phosphatase complex that dephosphorylates gammaH2AX regulates DNA damage checkpoint recovery. *Nature* **439**, 497-501 (2006).
109. Klein, H. L. Mutations in recombinational repair and in checkpoint control genes suppress the lethal combination of srs2Delta with other DNA repair genes in *Saccharomyces cerevisiae*. *Genetics* **157**, 557-65 (2001).
110. Kokoska, R. J. et al. Destabilization of yeast micro- and minisatellite DNA sequences by mutations affecting a nuclease involved in Okazaki fragment processing (rad27) and DNA polymerase delta (pol3-t). *Mol Cell Biol* **18**, 2779-88 (1998).
111. Krogan, N. J. et al. A Snf2 family ATPase complex required for recruitment of the histone H2A variant Htz1. *Mol Cell* **12**, 1565-76 (2003).
112. Lambertson, D., Chen, L. & Madura, K. Pleiotropic defects caused by loss of the proteasome-interacting factors Rad23 and Rpn10 of *Saccharomyces cerevisiae*. *Genetics* **153**, 69-79 (1999).
113. Lee, B. S., Bi, L., Garfinkel, D. J. & Bailis, A. M. Nucleotide excision repair/TFIIH helicases RAD3 and SSL2 inhibit short-sequence recombination and Ty1 retrotransposition by similar mechanisms. *Mol Cell Biol* **20**, 2436-45 (2000).
114. Lee, S. K., Johnson, R. E., Yu, S. L., Prakash, L. & Prakash, S. Requirement of yeast SGS1 and SRS2 genes for replication and transcription. *Science* **286**, 2339-42 (1999).

115. Li, L., Murphy, K. M., Kanevets, U. & Reha-Krantz, L. J. Sensitivity to phosphonoacetic acid: a new phenotype to probe DNA polymerase delta in *Saccharomyces cerevisiae*. *Genetics* **170**, 569-80 (2005).
116. Lo, Y. C. et al. Sgs1 regulates gene conversion tract lengths and crossovers independently of its helicase activity. *Mol Cell Biol* **26**, 4086-94 (2006).
117. Malone, R. E. & Hoekstra, M. F. Relationships between a hyper-rec mutation (REM1) and other recombination and repair genes in yeast. *Genetics* **107**, 33-48 (1984).
118. Moreau, S., Ferguson, J. R. & Symington, L. S. The nuclease activity of Mre11 is required for meiosis but not for mating type switching, end joining, or telomere maintenance. *Mol Cell Biol* **19**, 556-66 (1999).
119. Morrison, A., Johnson, A. L., Johnston, L. H. & Sugino, A. Pathway correcting DNA replication errors in *Saccharomyces cerevisiae*. *Embo J* **12**, 1467-73 (1993).
120. Mullen, J. R., Kaliraman, V., Ibrahim, S. S. & Brill, S. J. Requirement for three novel protein complexes in the absence of the Sgs1 DNA helicase in *Saccharomyces cerevisiae*. *Genetics* **157**, 103-18 (2001).
121. O'Neill, B. M., Hanway, D., Winzeler, E. A. & Romesberg, F. E. Coordinated functions of WSS1, PSY2 and TOF1 in the DNA damage response. *Nucleic Acids Res* **32**, 6519-30 (2004).
122. Onodera, R. et al. Functional and physical interaction between Sgs1 and Top3 and Sgs1-independent function of Top3 in DNA recombination repair. *Genes Genet Syst* **77**, 11-21 (2002).
123. Ooi, S. L., Shoemaker, D. D. & Boeke, J. D. DNA helicase gene interaction network defined using synthetic lethality analyzed by microarray. *Nat Genet* **35**, 277-86 (2003).
124. Pan, X. et al. A robust toolkit for functional profiling of the yeast genome. *Mol Cell* **16**, 487-96 (2004).
125. Pan, X. et al. A DNA integrity network in the yeast *Saccharomyces cerevisiae*. *Cell* **124**, 1069-81 (2006).
126. Paulovich, A. G., Armour, C. D. & Hartwell, L. H. The *Saccharomyces cerevisiae* RAD9, RAD17, RAD24 and MEC3 genes are required for tolerating irreparable, ultraviolet-induced DNA damage. *Genetics* **150**, 75-93 (1998).
127. Sokolsky, T. & Alani, E. EXO1 and MSH6 are high-copy suppressors of conditional mutations in the MSH2 mismatch repair gene of *Saccharomyces cerevisiae*. *Genetics* **155**, 589-99 (2000).
128. Soustelle, C. et al. A new *Saccharomyces cerevisiae* strain with a mutant Smt3-deconjugating Ulp1 protein is affected in DNA replication and requires Srs2 and homologous recombination for its viability. *Mol Cell Biol* **24**, 5130-43 (2004).
129. Symington, L. S. Homologous recombination is required for the viability of rad27 mutants. *Nucleic Acids Res* **26**, 5589-95 (1998).
130. Tishkoff, D. X., Filosi, N., Gaida, G. M. & Kolodner, R. D. A novel mutation avoidance mechanism dependent on *S. cerevisiae* RAD27 is distinct from DNA mismatch repair. *Cell* **88**, 253-63 (1997).
131. Tong, A. H. et al. Systematic genetic analysis with ordered arrays of yeast deletion mutants. *Science* **294**, 2364-8 (2001).

132. Tong, A. H. et al. Global mapping of the yeast genetic interaction network. *Science* **303**, 808-13 (2004).
133. Torres, J. Z., Schnakenberg, S. L. & Zakian, V. A. Saccharomyces cerevisiae Rrm3p DNA helicase promotes genome integrity by preventing replication fork stalling: viability of rrm3 cells requires the intra-S-phase checkpoint and fork restart activities. *Mol Cell Biol* **24**, 3198-212 (2004).
134. Tran, P. T., Erdeniz, N., Dudley, S. & Liskay, R. M. Characterization of nuclease-dependent functions of Exo1p in Saccharomyces cerevisiae. *DNA Repair (Amst)* **1**, 895-912 (2002).
135. Valay, J. G. et al. The KIN28 gene is required both for RNA polymerase II mediated transcription and phosphorylation of the Rpb1p CTD. *J Mol Biol* **249**, 535-44 (1995).
136. Vallen, E. A. & Cross, F. R. Mutations in RAD27 define a potential link between G1 cyclins and DNA replication. *Mol Cell Biol* **15**, 4291-302 (1995).
137. Wagner, M., Price, G. & Rothstein, R. The absence of Top3 reveals an interaction between the Sgs1 and Pif1 DNA helicases in Saccharomyces cerevisiae. *Genetics* **174**, 555-73 (2006).
138. Weitao, T., Budd, M. & Campbell, J. L. Evidence that yeast SGS1, DNA2, SRS2, and FOB1 interact to maintain rDNA stability. *Mutat Res* **532**, 157-72 (2003).
139. Xie, Y., Counter, C. & Alani, E. Characterization of the repeat-tract instability and mutator phenotypes conferred by a Tn3 insertion in RFC1, the large subunit of the yeast clamp loader. *Genetics* **151**, 499-509 (1999).
140. Yamana, Y. et al. Regulation of homologous integration in yeast by the DNA repair proteins Ku70 and RecQ. *Mol Genet Genomics* **273**, 167-76 (2005).
141. Zhao, R. et al. Navigating the chaperone network: an integrative map of physical and genetic interactions mediated by the hsp90 chaperone. *Cell* **120**, 715-27 (2005).
142. Branzei, D. et al. Ubc9- and mms21-mediated sumoylation counteracts recombinogenic events at damaged replication forks. *Cell* **127**, 509-22 (2006).
143. Branzei, D., Seki, M., Onoda, F. & Enomoto, T. The product of Saccharomyces cerevisiae WHIP/MGS1, a gene related to replication factor C genes, interacts functionally with DNA polymerase delta. *Mol Genet Genomics* **268**, 371-86 (2002).
144. Budd, M. E. et al. A network of multi-tasking proteins at the DNA replication fork preserves genome stability. *PLoS Genet* **1**, e61 (2005).
145. Chanet, R. & Heude, M. Characterization of mutations that are synthetic lethal with pol3-13, a mutated allele of DNA polymerase delta in Saccharomyces cerevisiae. *Curr Genet* **43**, 337-50 (2003).
146. Chang, M. et al. RMI1/NCE4, a suppressor of genome instability, encodes a member of the RecQ helicase/Topo III complex. *Embo J* **24**, 2024-33 (2005).
147. Chakhparonian, M., Faucher, D. & Wellinger, R. J. A mutation in yeast Tel1p that causes differential effects on the DNA damage checkpoint and telomere maintenance. *Curr Genet* **48**, 310-22 (2005).
148. Gabrielse, C. et al. A Dbf4p BRCA1 C-terminal-like domain required for the response to replication fork arrest in budding yeast. *Genetics* **173**, 541-55 (2006).

149. Gibson, D. G., Aparicio, J. G., Hu, F. & Aparicio, O. M. Diminished S-phase cyclin-dependent kinase function elicits vital Rad53-dependent checkpoint responses in *Saccharomyces cerevisiae*. *Mol Cell Biol* **24**, 10208-22 (2004).
150. Hu, F., Alcasabas, A. A. & Elledge, S. J. Asf1 links Rad53 to control of chromatin assembly. *Genes Dev* **15**, 1061-6 (2001).
151. Huang, M. & Elledge, S. J. Identification of RNR4, encoding a second essential small subunit of ribonucleotide reductase in *Saccharomyces cerevisiae*. *Mol Cell Biol* **17**, 6105-13 (1997).
152. Huang, P. et al. SGS1 is required for telomere elongation in the absence of telomerase. *Curr Biol* **11**, 125-9 (2001).
153. Loeillet, S. et al. Genetic network interactions among replication, repair and nuclear pore deficiencies in yeast. *DNA Repair (Amst)* **4**, 459-68 (2005).
154. Izbicka, E. et al. Alterations in DNA repair and telomere maintenance mechanism affect response to porphyrins in yeast. *Anticancer Res* **21**, 1899-903 (2001).
155. Klein, H. L. Spontaneous chromosome loss in *Saccharomyces cerevisiae* is suppressed by DNA damage checkpoint functions. *Genetics* **159**, 1501-9 (2001).
156. Nugent, C. I. et al. Telomere maintenance is dependent on activities required for end repair of double-strand breaks. *Curr Biol* **8**, 657-60 (1998).
157. Reis, C. C. & Campbell, J. L. Contribution of Trf4/5 and the nuclear exosome to genome stability through regulation of histone mRNA levels in *Saccharomyces cerevisiae*. *Genetics* **175**, 993-1010 (2007).
158. Chen, X. L. et al. Topoisomerase I-dependent viability loss in *saccharomyces cerevisiae* mutants defective in both SUMO conjugation and DNA repair. *Genetics* **177**, 17-30 (2007).
159. Tsukamoto, Y., Mitsuoka, C., Terasawa, M., Ogawa, H. & Ogawa, T. Xrs2p regulates Mre11p translocation to the nucleus and plays a role in telomere elongation and meiotic recombination. *Mol Biol Cell* **16**, 597-608 (2005).
160. Vijeh Motlagh, N. D., Seki, M., Branzei, D. & Enomoto, T. Mgs1 and Rad18/Rad5/Mms2 are required for survival of *Saccharomyces cerevisiae* mutants with novel temperature/cold sensitive alleles of the DNA polymerase delta subunit, Pol31. *DNA Repair (Amst)* **5**, 1459-74 (2006).
161. Viscardi, V., Baroni, E., Romano, M., Lucchini, G. & Longhese, M. P. Sudden telomere lengthening triggers a Rad53-dependent checkpoint in *Saccharomyces cerevisiae*. *Mol Biol Cell* **14**, 3126-43 (2003).
162. Zhao, X., Chabes, A., Domkin, V., Thelander, L. & Rothstein, R. The ribonucleotide reductase inhibitor Sml1 is a new target of the Mec1/Rad53 kinase cascade during growth and in response to DNA damage. *Embo J* **20**, 3544-53 (2001).
163. Fabre, F., Chan, A., Heyer, W. D. & Gangloff, S. Alternate pathways involving Sgs1/Top3, Mus81/ Mms4, and Srs2 prevent formation of toxic recombination intermediates from single-stranded gaps created by DNA replication. *Proc Natl Acad Sci U S A* **99**, 16887-92 (2002).
164. Gangloff, S., Soustelle, C. & Fabre, F. Homologous recombination is responsible for cell death in the absence of the Sgs1 and Srs2 helicases. *Nat Genet* **25**, 192-4 (2000).

165. Gellon, L., Barbey, R., Auffret van der Kemp, P., Thomas, D. & Boiteux, S. Synergism between base excision repair, mediated by the DNA glycosylases Ntg1 and Ntg2, and nucleotide excision repair in the removal of oxidatively damaged DNA bases in *Saccharomyces cerevisiae*. *Mol Genet Genomics* **265**, 1087-96 (2001).
166. Hayashi, N. & Murakami, S. STM1, a gene which encodes a guanine quadruplex binding protein, interacts with CDC13 in *Saccharomyces cerevisiae*. *Mol Genet Genomics* **267**, 806-13 (2002).
167. Mankouri, H. W., Craig, T. J. & Morgan, A. SGS1 is a multicopy suppressor of *srs2*: functional overlap between DNA helicases. *Nucleic Acids Res* **30**, 1103-13 (2002).
168. Ortolan, T. G. et al. The DNA repair protein rad23 is a negative regulator of multi-ubiquitin chain assembly. *Nat Cell Biol* **2**, 601-8 (2000).
169. Archambault, V., Ikui, A. E., Drapkin, B. J. & Cross, F. R. Disruption of mechanisms that prevent rereplication triggers a DNA damage response. *Mol Cell Biol* **25**, 6707-21 (2005).
170. Kanellis, P., Agyei, R. & Durocher, D. Elg1 forms an alternative PCNA-interacting RFC complex required to maintain genome stability. *Curr Biol* **13**, 1583-95 (2003).
171. Ragu, S. et al. Oxygen metabolism and reactive oxygen species cause chromosomal rearrangements and cell death. *Proc Natl Acad Sci U S A* **104**, 9747-52 (2007).
172. Robinson, M. et al. The Gcs1 Arf-GAP mediates Snc1,2 v-SNARE retrieval to the Golgi in yeast. *Mol Biol Cell* **17**, 1845-58 (2006).
173. Miki, Y. et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. *Science* **266**, 66-71 (1994).
174. Wooster, R. et al. Identification of the breast cancer susceptibility gene BRCA2. *Nature* **378**, 789-92 (1995).
175. Hiramoto, T. et al. Mutations of a novel human RAD54 homologue, RAD54B, in primary cancer. *Oncogene* **18**, 3422-6 (1999).
176. Schoenmakers, E. F., Huysmans, C. & Van de Ven, W. J. Allelic knockout of novel splice variants of human recombination repair gene RAD51B in t(12;14) uterine leiomyomas. *Cancer Res* **59**, 19-23 (1999).
177. Wong, A. K. et al. Characterization of a carboxy-terminal BRCA1 interacting protein. *Oncogene* **17**, 2279-85 (1998).
178. Giannini, G. et al. Human MRE11 is inactivated in mismatch repair-deficient cancers. *EMBO Rep* **3**, 248-54. (2002).
179. Riballo, E. et al. Identification of a defect in DNA ligase IV in a radiosensitive leukaemia patient. *Curr Biol* **9**, 699-702 (1999).
180. Moshous, D. et al. Partial T and B lymphocyte immunodeficiency and predisposition to lymphoma in patients with hypomorphic mutations in Artemis. *J Clin Invest* **111**, 381-7 (2003).
181. Fishel, R. et al. The human mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer. *Cell* **75**, 1027-38 (1993).
182. Papadopoulos, N. et al. Mutation of a mutL homolog in hereditary colon cancer. *Science* **263**, 1625-9 (1994).

183. Wijnen, J. et al. Familial endometrial cancer in female carriers of MSH6 germline mutations. *Nat Genet* **23**, 142-4 (1999).
184. Nicolaides, N. C. et al. Mutations of two PMS homologues in hereditary nonpolyposis colon cancer. *Nature* **371**, 75-80 (1994).
185. Lipkin, S. M. et al. Germline and somatic mutation analyses in the DNA mismatch repair gene MLH3: Evidence for somatic mutation in colorectal cancers. *Hum Mutat* **17**, 389-96 (2001).
186. German, J., Bloom, D. & Passarge, E. Bloom's syndrome. V. Surveillance for cancer in affected families. *Clin Genet* **12**, 162-8 (1977).
187. Mohaghegh, P. & Hickson, I. D. DNA helicase deficiencies associated with cancer predisposition and premature ageing disorders. *Hum Mol Genet* **10**, 741-6 (2001).
188. Vorechovsky, I. et al. Clustering of missense mutations in the ataxia-telangiectasia gene in a sporadic T-cell leukaemia. *Nat Genet* **17**, 96-9 (1997).
189. Menisser-de Murcia, J., Mark, M., Wendling, O., Wynshaw-Boris, A. & de Murcia, G. Early embryonic lethality in PARP-1 Atm double-mutant mice suggests a functional synergy in cell proliferation during development. *Mol Cell Biol* **21**, 1828-32. (2001).
190. Bryant, H. E., Ying, S. & Helleday, T. Homologous recombination is involved in repair of chromium-induced DNA damage in mammalian cells. *Mutat Res* **599**, 116-23 (2006).
191. Matsuura, S. et al. Positional cloning of the gene for Nijmegen breakage syndrome. *Nat Genet* **19**, 179-81 (1998).
192. Levine, A. J., Momand, J. & Finlay, C. A. The p53 tumour suppressor gene. *Nature* **351**, 453-6 (1991).
193. Bell, D. W. et al. Heterozygous germ line hCHK2 mutations in Li-Fraumeni syndrome. *Science* **286**, 2528-31 (1999).
194. Tanaka, K. et al. Analysis of a human DNA excision repair gene involved in group A xeroderma pigmentosum and containing a zinc-finger domain. *Nature* **348**, 73-6 (1990).
195. Weeda, G. et al. A presumed DNA helicase encoded by ERCC-3 is involved in the human repair disorders xeroderma pigmentosum and Cockayne's syndrome. *Cell* **62**, 777-91 (1990).
196. Masutani, C. et al. Purification and cloning of a nucleotide excision repair complex involving the xeroderma pigmentosum group C protein and a human homologue of yeast RAD23. *Embo J* **13**, 1831-43 (1994).
197. Arrand, J. E., Bone, N. M. & Johnson, R. T. Molecular cloning and characterization of a mammalian excision repair gene that partially restores UV resistance to xeroderma pigmentosum complementation group D cells. *Proc Natl Acad Sci U S A* **86**, 6997-7001 (1989).
198. Nichols, A. F., Ong, P. & Linn, S. Mutations specific to the xeroderma pigmentosum group E Ddb- phenotype. *J Biol Chem* **271**, 24317-20 (1996).
199. Norris, P. G., Hawk, J. L., Avery, J. A. & Giannelli, F. Xeroderma pigmentosum complementation group F in a non-Japanese patient. *J Am Acad Dermatol* **18**, 1185-8 (1988).

200. Cheng, L., Sturgis, E. M., Eicher, S. A., Spitz, M. R. & Wei, Q. Expression of nucleotide excision repair genes and the risk for squamous cell carcinoma of the head and neck. *Cancer* **94**, 393-7 (2002).
201. Johnson, R. E., Kondratik, C. M., Prakash, S. & Prakash, L. hRAD30 mutations in the variant form of xeroderma pigmentosum. *Science* **285**, 263-5 (1999).
202. Tischkowitz, M. & Dokal, I. Fanconi anaemia and leukaemia - clinical and molecular aspects. *Br J Haematol* **126**, 176-91 (2004).
203. Wang, L., Patel, U., Ghosh, L. & Banerjee, S. DNA polymerase beta mutations in human colorectal cancer. *Cancer Res* **52**, 4824-7 (1992).
204. Zheng, L. et al. Fen1 mutations result in autoimmunity, chronic inflammation and cancers. *Nat Med* **13**, 812-9 (2007).

Figure 1




Figure 2





Figure 3



	GENOTYPE	OUTCOME	BIOMARKERS
INITIAL CANCER MUTATION	A B C D E	→ SURVIVAL	Elevated B activity, Lost A posttranslational modifications
B INHIBITOR IN CANCER CELLS	A B C D E	→ LETHAL	
B INHIBITOR IN NORMAL CELLS	A B C D E	→ SURVIVAL	D+E activity, Lost A+B+C posttranslational modifications
DRUG RESISTANT MUTATION	A B C D E	→ SURVIVAL	
2ND THERAPY IN CANCER CELLS	A B C D E	→ SURVIVAL	
2ND THERAPY IN RESISTANT CELLS	A B C D E	→ LETHAL	
2ND THERAPY IN NORMAL CELLS	A B C D E	→ SURVIVAL	

~~⊗~~ Targeted monotherapy
~~⊗~~ Cancer mutation

Figure 4

